The Food and Drug Administration (FDA) is now navigating a future under Robert F. Kennedy Jr., who has pledged to relax regulations to make alternative therapies more accessible. This shift could impact the agency’s ability to ensure the safety of medical treatments.
Kennedy’s commitment to reducing bureaucratic hurdles may lead to the availability of alternative therapies that lack rigorous scientific validation. This development raises concerns about the potential risks to public health and the integrity of medical standards.